Davids MS, Ryan CE, Lampson BL, Ren Y, et al. Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naive Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease. J Clin Oncol 2025 Mar 18:JCO2500466. doi: 10.1200/JCO-25-00466.
PMID: 40101168